The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Launching in 2022, its availability will be expanded to the global market
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
New study presents a human-relevant stress model for assessing potential therapeutics
Investment to expand manufacturing and global medicine supply capacity
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Subscribe To Our Newsletter & Stay Updated
